1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Capital Allocation
INVESTOR
Adept at partnerships and acquisitions, Bristol-Myers Squibb has built a strong portfolio of drugs and a robust pipeline. This strategy is seen with its large acquisition of Celgene, which netted the firm an excellent pipeline and a strong entrenchment in blood cancer. We believe the strong overall pipeline helps support its wide moat.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of BMY’s competitive advantage.
Bristol-Myers Squibb Co
XNYS: BMY
| Eli Lilly and Co
XNYS: LLY
| Merck & Co Inc
XNYS: MRK
| Pfizer Inc
XNYS: PFE
| |
Price
| 64.80 | 446.04 | 110.71 | 38.97 |
Currency
| USD | USD | USD | USD |
Change
| −$0.51 (0.78%) | +$0.38 (0.09%) | +$0.39 (0.35%) | −$0.12 (0.31%) |
Market Cap
| 136.13 Bil | 423.41 Bil | 280.92 Bil | 220.00 Bil |
Industry
| Drug Manufacturers - General | Drug Manufacturers - General | Drug Manufacturers - General | Drug Manufacturers - General |
Sector
|
Healthcare
|
Healthcare
|
Healthcare
|
Healthcare
|
* Trading data in this section is delayed by at least 15 minutes.
Yes. BMY has a forward dividend yield of 3.52%.
See
BMY’s full dividends and stock split history
on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
BMY’s market cap is 136.13 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
BMY’s stock style is Large Value.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
BMY’s price/sales is 3.02.
Price/sales represents the amount an investor is willing to pay for a dollar generated from
a particular company’s sales or revenues.
BMY’s price/forward earnings is 18.89.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates.
The lower the Forward P/E, the cheaper the stock.
BMY’s price/book is 4.28.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets,
based on historical, rather than current, valuations. Historical valuations generally do not reflect
a company’s current market value. Value investors frequently look for companies that have low price/book ratios.
See BMY’s valuation ratios compared to the Market Index.
BMY’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare BMY’s historical performance against its industry peers and the overall market.
